Business Wire Industry News

Monday, March 18, 2019

Dr Joshua Dunaief MD, Renowned Age-Related Macular Degeneration Clinician and Researcher, Joins Mperia Therapeutics Inc. Clinical Advisory Board

MONTREAL--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/amorchem?src=hash" target="_blank"gt;#amorchemlt;/agt;--Dr. Joshua Dunaief, PhD, MD, the Adele Niessen Professor of Ophthalmology, Scheie Eye Institute, University of Pennsylvania, USA, joins the Clinical Advisory Board (CAB) of Mperia Therapeutics Inc. “A front-line Age-Related Macular Degeneration (AMD) clinician for two decades, combined with a stellar research reputation around oxidative stress in the eye, means Dr Dunaief is the perfect final appointee to our CAB as we finalize our clinical Phase 1 and 2 plans,” state

Friday, March 15, 2019

Enigma Biomedical Group Signs License Agreement with Merck for Novel MK-6884 Imaging Agent

TORONTO--(BUSINESS WIRE)--Enigma Biomedical Group (EBG) today announced an exclusive license agreement with Merck, known as MSD outside the US and Canada, for the global development and commercialization of MK-6884, an early stage investigational imaging agent developed by Merck for use in Positron Emission Tomography (PET) scans to measure cholinergic tone change in vivo. MK-6884 has potential applications as an imaging agent across multiple neurodegenerative diseases. As part of the agreement

Thursday, March 14, 2019

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Introduces Full Year 2019 Outlook

NEWTOWN, Pa.--(BUSINESS WIRE)--Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the fourth quarter and full year ended December 31, 2018. Full Year 2018 Financial Summary Revenue of $0.5 million, compared to no revenue in 2017. Operating loss of $26.7 million, compared to operating loss of $22.9 million in 2017. Net loss of $28.6 million, compared to net loss of $28.0

Thursday, March 14, 2019

Altasciences Receives CRO Leadership Award in Five Categories

LAVAL, Quebec--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Altasciences?src=hash" target="_blank"gt;#Altascienceslt;/agt;--Altasciences, a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug development, announced today that it has been awarded a 2019 CRO Leadership Award in five different categories. For the 2019 CRO Leadership Awards, Life Science Leader magazine once again teamed up with Industry Standard Research (ISR) to determine the award recipients. This is the fourth year that Altasciences has been recognized by the indust

Thursday, March 14, 2019

AbCellera Signs Agreement with Global Health Foundation to Fight Infectious Disease

VANCOUVER, British Columbia--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/antibodies?src=hash" target="_blank"gt;#antibodieslt;/agt;--Global health research will benefit from AbCellera's human antibody discovery and immune repertoire profiling technology through two-year agreement.

Thursday, March 14, 2019

Contextual Genomics Names Michael Ball as Chief Executive Officer

VANCOUVER, British Columbia--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/cancergenomics?src=hash" target="_blank"gt;#cancergenomicslt;/agt;--Contextual Genomics, a leading Canadian cancer genomics company, announced today that its Board of Directors has named Michael Ball as Chief Executive Officer. Mr. Ball was previously Global Vice President Commercial, Informatics, at Illumina, a market leader in the genomics industry. Prior to Illumina, Mr. Ball was the CEO of GenoLogics Life Sciences Software, a leading provider of informatics solutions for clinical genomics and precision medicine.

Wednesday, March 13, 2019

Conavi Medical Announces Health Canada Approval of Novasight Hybrid System for Visualization During Coronary Angioplasty Procedures

TORONTO--(BUSINESS WIRE)--Conavi Medical Inc. (www.conavi.com) is pleased to announce that it has received a Health Canada Medical Device License for the Novasight HybridTM System. This patented technology is the only clinical system that enables simultaneous imaging of coronary arteries with both intravascular ultrasound (IVUS) and optical coherence tomography (OCT), and was invented at Sunnybrook Research Institute. Angioplasty and stenting is performed four million times around the world eve

Wednesday, March 13, 2019

Tilray® Expands Global Leadership Team with Appointment of Chief Corporate Development Officer

NANAIMO, British Columbia--(BUSINESS WIRE)--Today, Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announces the expansion of its global senior leadership team with the appointment of Andrew Pucher as Chief Corporate Development Officer. In his new role, Andrew will lead Tilray’s corporate development function, including the team that is responsible for M&A and corporate investments. He will be based in Toronto, ON, and report to